Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets

This study has been completed.
Sponsor:
Information provided by:
Kremers Urban Development Company
ClinicalTrials.gov Identifier:
NCT01179646
First received: August 10, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

The objective of this study was to determine the single-dose bioequivalence of the test product, a potential generic 40 mg pantoprazole delayed-release tablet formulation, compared with the reference product, a pantoprazole 40 mg delayed-release tablet formulation (Protonix, Wyeth Pharmaceuticals), following a single dose in the fasted state.


Condition Intervention Phase
Healthy
Drug: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in the Fasted State

Resource links provided by NLM:


Further study details as provided by Kremers Urban Development Company:

Primary Outcome Measures:
  • Cmax (maximum observed concentration of drug substance in plasma) [ Time Frame: 16 hours ] [ Designated as safety issue: No ]
  • AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration) [ Time Frame: 16 hours ] [ Designated as safety issue: No ]
  • AUC0-inf area under the concentration-time curve from time zero to infinity) [ Time Frame: 16 hoyurs ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: June 2004
Study Completion Date: August 2004
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Protonix
Protonix 40 mg DR Tablet
Drug: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Single dose crossover BE study
Other Name: Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
Experimental: Pantoprazole
Pantoprazole 40 mg DR Tablet
Drug: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Single dose crossover BE study
Other Name: Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)

Detailed Description:

The 90% CI for pantoprazole ln(Cmax), ln[AUC(0-t)], and ln[AUC(0-inf)] for the comparison of the test product (pantoprazole) versus the reference product (Protonix) should be within the 80 to 125% range required for the conclusion of bioequivalence.

  Eligibility

Ages Eligible for Study:   19 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non tobacco/nicotine-using (6 months minimum) healthy males and females between 19 and 50 years of age.
  • Body weight from 15% below or 15% above, inclusive, the ideal weight for height and estimated frame, as adapted from the 1983 Metropolitan Life Table.
  • Female subjects were surgically sterile, at least two years postmenopausal, or if sexually active, had a partner who had been vasectomized for at least 6 months, or agreed to utilize one of the following forms of contraception: barrier (condom with spermicide or diaphragm with spermicide), IUD, or hormonal (oral, implant, transdermal patch, or injection) for the following specified times.

Subjects using hormonal contraceptives were on a stable dose for 3 months prior to dosing, or they agreed to also use a barrier method of birth control from screening through completion of the study. Subjects having an intrauterine device (IUD) must have had the IUD in place for at least 2 months prior to dosing, or they agreed to also use a barrier method of birth control from screening through completion of the study. For other forms of birth control, the subject had used the method at least 2 weeks prior to screening and agreed to use the method through completion of the study.

  • Voluntary consent to participate in this study as demonstrated by signing the informed consent form.

Exclusion Criteria:

  • Persons of Asian origin.
  • Females who were pregnant or lactating.
  • History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject or impact the validity of the study results.
  • History of hypersensitivity, allergic or adverse response to pantoprazole or related drugs.
  • Positive results from HIV antibody screen, hepatitis B surface antigen screen, and/or hepatitis C antibody screen.
  • Participation in a previous clinical trial within 30 days prior to study initiation.
  • Donation of one pint or more of whole blood within 56 days prior to study initiation.
  • Donation of 2 units of red blood cells within 112 days prior to study initiation.
  • Donation of plasma with 7 days prior to study initiation.
  • Difficulty in swallowing medication or any gastrointestinal disease that could affect the drug absorption.
  • Abnormal diet or substantial changes in eating habits within 30 days prior to study initiation. Examples included, but were not limited to, vegetarian, fasting, or liquid supplement, etc.
  • Treatment with any known enzyme-altering agents (barbiturates, phenothiazines, or cimetidine, etc.) within 30 days prior to study initiation.
  • Use of any prescription medication (except hormonal contraceptives for females) within 14 days prior to study initiation.
  • Use of any over-the-counter (OTC) medication, including mega-dose vitamins, analgesics, herbal/nutritional supplements, and antacids, within 7 days prior to study initiation.
  • Positive urine screen for alcohol or drugs of abuse.
  • Unwilling to eat the food as provided in the study menu.
  • Hemoglobin <12.0 g/dL.
  • History of alcohol or drug abuse within 2 years prior to dosing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01179646

Locations
United States, Nebraska
MDS Pharma Services
Lincoln, Nebraska, United States, 68502
Sponsors and Collaborators
Kremers Urban Development Company
Investigators
Principal Investigator: Alan Marion, MD, PhD MDS Pharma Services
  More Information

No publications provided

Responsible Party: Alan S. Marion, MD, PhD, MDS Pharma Services (US) Inc.
ClinicalTrials.gov Identifier: NCT01179646     History of Changes
Other Study ID Numbers: SP796
Study First Received: August 10, 2010
Last Updated: August 10, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Kremers Urban Development Company:
Bioequivalency

Additional relevant MeSH terms:
Pantoprazole
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 20, 2014